Comparing non-vertebral fracture risk reduction with osteoporosis therapies: Looking beneath the surface

Osteoporosis International

Volumn 20, Issue 5, 2009, Pages 675-686

  Sebba, A ^a  

^a NONE   (United States)

Author keywords

Alendronate; Bisphosphonate; Ibandronate; Non vertebral fractures; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE TISSUE; BONE TURNOVER; CLINICAL TRIAL; COMPARATIVE STUDY; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG DOSE COMPARISON; FRACTURE; FRAGILITY FRACTURE; HUMAN; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; RESEARCH DESIGN; RISK FACTORS; RISK REDUCTION BEHAVIOR; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 63949084336     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0802-0     Document Type: Review

References (50)

1. JP Empana P Dargent-Molina G Breart 2004 Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study J Am Geriatr Soc 52 685 690
2. DM Kado WS Browner L Palermo 1999 Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group Arch Intern Med 159 1215 1220
3. Division of Metabolic and Endocrine Drug Products (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Available at: http://www.fda.gov/cder/ guidance/osteo.pdf. Accessed January 24, 2008
4. CM Klotzbuecher PD Ross PB Landsman 2000 Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis J Bone Miner Res 15 721 739
5. RD Wasnich 1996 Vertebral fracture epidemiology Bone 18 3 Suppl 179S 183S
6. BL Riggs LJ Melton 3rd WM O'Fallon 1996 Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy Bone 18 3 Suppl 197S 201S
7. National Osteoporosis Foundation. Fast Facts (2008) NOF Web site. Available at: www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 8, 2008
8. R Eastell DM Reid J Compston 2001 Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? Q J Med 94 575 597
9. LJ Melton EA Chrischilles C Cooper 1992 How many women have osteoporosis J Bone Miner Res 7 1005 1010
10. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Executive Summary (2004) USHHS Web site. Available at: http://www.surgeongeneral.gov/library/bonehealth. Accessed January 26, 2008
11. DM Black SR Cummings DB Karpf 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541
12. HG Bone SL Greenspan C McKeever 2000 Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group J Clin Endocrinol Metab 85 720 726
13. Bonnick S, Hochberg M, Broy S, et al (2005) Comparison of once-weekly alendronate and once-weekly risedronate in the osteoporotic subgroup from the FACT study. Presented at The Sixth International Symposium on Osteoporosis: Current Status and Future Directions: April 6-10; Washington, DC
14. AI Sebba SL Bonnick R Kagan 2004 Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis Curr Med Res Opin 20 2031 2041
15. SL Silverman NB Watts PD Delmas 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 25 34
16. J Reginster HW Minne OH Sorensen 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91
17. ST Harris NB Watts HK Genant 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
18. MR McClung P Geusens PD Miller 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340
19. UA Liberman SR Weiss J Bröll 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443
20. SR Cummings DM Black DE Thompson 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 2082
21. CH Chesnut III A Skag C Christiansen 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 1241 1249
22. DM Black PD Delmas R Eastell 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
23. RM Neer CD Arnaud JR Zanchetta 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441
24. B Ettinger DM Black BH Mitlak 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial JAMA 282 637 645
25. CH Chesnut 3rd S Silverman K Andriano 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 109 267 276
26. JC Gallagher HK Genant GG Crans 2005 Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures J Clin Endocrinol Metab 90 1583 1587
27. DM Black DE Thompson DC Bauer 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial J Clin Endocrinol Metab 85 4118 4124
28. RG Russell 2007 Bisphosphonates: mode of action and pharmacology Pediatrics 119 Suppl 2 S150 S156
29. Boniva Tablets [package insert] (2006) Roche Pharmaceuticals, Nutley, NJ
30. HG Bone RW Downs Jr JR Tucci 1997 Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers J Clin Endocrinol Metab 82 265 274
31. R Lindsay SL Silverman C Cooper 2001 Risk of new vertebral fracture in the year following a fracture JAMA 285 320 323
32. DJ Torgerson MK Campbell RE Thomas 1996 Prediction of perimenopausal fractures by bone mineral density and other risk factors J Bone Miner Res 11 293 297
33. World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report. Brussels, Belgium, May 5-7, 2004. Available at: www.who.int/entity/chp/topics/ Osteoporosis.pdf. Accessed January 28, 2008
34. EM Lewiecki NB Watts MR McClung 2004 Official positions of the international society for clinical densitometry J Clin Endocrinol Metab 89 3651 3655
35. WD Leslie JF Tsang PA Caetano for the Manitoba Bone Density Program 2007 Number of osteoporotic sites and fracture risk assessment: a cohort study from the Manitoba Bone Density Program J Bone Miner Res 22 476 483
36. A Papaioannou L Joseph G Ioannidis 2005 Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos) Osteoporos Int 16 568 578
37. HA Pols D Felsenberg DA Hanley 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group Osteoporos Int 9 461 468
38. D Black L Palermo H Pols 2002 Reductions in non-vertebral fracture with alendronate depend on baseline BMD: The FOSIT Study Osteoporos Int 13 Suppl 1 S22
39. DC Bauer P Garnero MC Hochberg 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 292 299
40. KW Lyles CS Colón-Emeric JS Magaziner 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809
41. IA Dontas CK Yiannakopoulos 2007 Risk factors and prevention of osteoporosis-related fractures J Musculoskelet Neuronal Interact 7 268 272
42. A Díez-Pérez J González-Macías F Marín 2007 Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound Osteoporos Int 18 629 639
43. KE Ensrud SK Ewing BC Taylor 2007 Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures J Gerontol A Biol Sci Med Sci 62 744 751
44. Bonnick SL (2004) Bone densitometry in clinical practice: application and interpretation, 2nd edn. Humana Press, Totowa, NJ, p 282
45. UA Liberman MC Hochberg P Geusens 2006 Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials Int J Clin Pract 60 1394 1400
46. S Boonen RF Laan IP Barton 2005 Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies Osteoporos Int 16 1291 1298
47. A Cranney G Wells A Willan 2002 Meta-analyses of alendronate for the treatment of postmenopausal women Endocr Rev 23 508 516
48. A Cranney G Guyatt L Griffith 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 578
49. ST Harris WA Blumentals PD Miller 2008 Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies Curr Med Res Opin 24 237 245
50. C Roux K Briot S Horlait 2007 Assessment of non-vertebral fracture risk in postmenopausal women Ann Rheum Dis 66 931 935